In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...
Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital. In April, in part 1 of ...
- Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 Arrowhead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback